Table 5.
Factor | HR | 95% CI | p-value |
---|---|---|---|
Age | |||
50 – 59 | 2.20 | 1.15 – 4.21 | 0.017* |
60 – 69 | 1.40 | 0.68 – 2.89 | 0.358 |
≥ 70 | 1.68 | 0.79 – 3.59 | 0.178 |
Breslow’s index | |||
1.01 – 2.00 mm | 0.93 | 0.48 – 1.80 | 0.822 |
2.01 – 4.00 mm | 0.65 | 0.32 – 1.32 | 0.229 |
≥ 4.01 mm | 1.43 | 0.65 – 3.15 | 0.375 |
Sex | |||
female | 1.03 | 0.61 – 1.72 | 0.921 |
Histologic subtype | |||
nodular type | 1.29 | 0.75 – 2.22 | 0.361 |
Mutational status | |||
BRAF | 0.75 | 0.39 – 1.46 | 0.388 |
NRAS | 2.01 | 1.02 – 3.98 | 0.045* |
SLNB | |||
positive | 0.95 | 0.51 – 1.79 | 0.877 |
Multivariate model for disease progression where death was considered a competing risk (competing risk model). The references for each factor were age < 50 years, Breslow’s thickness < 1.00 mm, male sex, non-nodular histologic subtype, WT for BRAF and NRAS, and negative SLNB status. Hazard ratios (HR) for progression and 95% confidence intervals (CI) are indicated; SLNB sentinel lymph node biopsy, ICB immune checkpoint blockade; *p < 0.05